Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

ABSTRACT: Purpose: The persistence of leukemia stem cells (LSC)-containing cells after induction therapy may contribute to minimal residual disease (MRD) and relapse in acute myeloid leukemia (AML). We investigated the clinical relevance of CD34⁺CD123⁺ LSC-containing cells and antileukemia potency of a novel antibody conjugate SL-101 in targeting CD123⁺ LSCs.Experimental Methods and Results: In a retrospective study on 86 newly diagnosed AML patients, we demonstrated that a higher proportion of CD34⁺CD123⁺ LSC-containing cells in remission was associated with persistent MRD and predicted shorter relapse-free survival in patients with poor-risk cytogenetics. Using flow cytometry, we explored the potential benefit of therapeutic targ

SUBMITTER: Han L 

PROVIDER: S-EPMC5496806 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature